Rhelion President Resigns; Subsidiary Ships PEX010 for Phase 1 Trial
Rhelion said subsidiary Filament shipped PEX010 to UCSF for a Phase 1 psilocybin trial in healthy older adults with low well-being. President Benjamin Lightburn resigned effective November 15, 2026, and will remain a director.